Bethanechol chloride in neurogenic bladder dysfunction.
Representative case summaries of patients with different types of neurogenic bladder diagnosed by combined cystometric-perineal electromyography and treated with bethanechol (Urecholine) are presented. Determination of the activity of the periurethral striated muscle in relation to bladder dysfunction is extremely important in the selection of patients for bethanechol therapy. In the absence of structural obstruction, bethanechol can be used in patients with (1) the early phase of coordinated reflex neurogenic bladder and sphincter when there is incomplete bladder emptying due to feeble or unsustained detrusor contractions, (2) recovery phase of spinal shock when the periurethral striated muscle has recovered and is under voluntary control, (3) incomplete motor paralytic bladder with coordinated sphincter, and (4) sensory paralytic bladder with decompensation. The bethanechol regimen will vary in accordance with the type of bladder being treated.
D000130:Achondroplasia / Q000150:complications; D000328:Adult; D001626:Bethanechol Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008159:Lumbar Vertebrae / Q000293:injuries; D008297:Male; D009101:Multiple Myeloma / Q000150:complications; D009126:Muscle Relaxation / Q000187:drug effects; D010264:Paraplegia / Q000150:complications; D012018:Reflex / Q000187:drug effects; D013117:Spinal Cord Compression / Q000150:complications; D013119:Spinal Cord Injuries / Q000150:complications; D013120:Spinal Cord Neoplasms / Q000150:complications; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D014546:Urinary Catheterization
D001626:Bethanechol Compounds